Jeffrey Greenstein is a Neurology physician affiliated with Multiple Sclerosis Research Institute. OpenAlex indexes 41 publications with 752 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1341 N Delaware Ave
Suite 212
Philadelphia, PA 191254300
Telephone
267-597-3830Registry record last updated 5 Jan 2012.
Clinical trials
- A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
Sponsor: Multiple Sclerosis Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
95.1%Integrin Receptor Antagonist94.1%Natalizumab100%Part B, office-administered≥19 patientsOther immunostimulants0.5%Glatiramer Acetate53%Copaxone47%Part D<11 patients+ 2 more classes in this area
Nervous system
2.8%Anti-epileptic Agent0.4%Oxcarbazepine100%Part D≥16 patientsGabapentinoids0.4%Gabapentin100%Part D≥23 patients+ 12 more classes in this area
Musculoskeletal
0.9%gamma-Aminobutyric Acid-ergic Agonist0.4%Baclofen100%Part D≥26 patientsCentral alpha-2 Adrenergic Agonist0.2%Tizanidine Hcl100%Part D≥14 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1985–1989 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
Multiple Sclerosis Journal - Experimental Translational and Clinical
2020 - Heptamer Peptide Disassembles Native Amyloid in Human Plasma Through Heat Shock Protein 70
Rejuvenation Research
2018
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”